Mouse monoclonal antibodies Bi and B3 are specific for natural and Escherichia coli-derived recombinant human V-interferon (IFN-y). The two antibodies recognize different epitopes of the IFN-y molecule and do not compete with each other's binding. We have used these two antibodies to construct a solid-phase, sandwich immunoradiometric assay for human IFN-y. Purified antibody Bi was coated on polystyrene beads (0.64 cm in diameter) and used as the solid-phase immunoadsorbent and antibody B3 was labeled with 1251 and used as tracer. This assay can be completed in about 4 hr and is capable of detecting IFN-y levels in human serum or tissue culture fluids as low as 0.1 NIH reference unit/mi. Recombinant human IFN-y derived from E. coli was detectable at a concentration of 0.02 ng/ml. The assay appears to be specific for the biologically active forms of IFN-y, since after exposure to pH 2, 370C, or 560C, biological activity and reactivity in the immunoradiometric assay decreased in parallel. The immunoradiometric assay can be employed for the analysis of the structural characteristics of the human IFN-y molecule.y-Interferon (IFN-y), also called immune IFN, is a lymphokine secreted by T lymphocytes upon stimulation with antigens or nonspecific mitogens (1)(2)(3)(4)(5)(6). Like IFN-a and -3(7-9), IFN-y induces the resistance of cells to viral infection and also exerts a range of immunoregulatory activities in vivo and in vitro, such as the augmentation of natural killer cell tumoricidal activity (4). In addition, IFN-y activates macrophages by triggering their morphological transformation, secretion of soluble factors, and expression of surface Ia antigens and Fc receptors (10, 11). Recent evidence also strongly suggests that IFN-y is indistinguishable from macrophage activation factor (12-16).Routine laboratory assays for IFNs are generally based on their ability to inhibit the lysis of cultured cells by viruses (17). Recently, two mouse monoclonal antibodies, B1 and B3, specific for natural and Escherichia coli-derived recombinant human IFN-y have been developed (18, 19). The two antibodies recognize different epitopes, since B1 and B3 differ in their reactivity with the IFN-y molecule (18) and they do not compete with each other's binding to IFN-y (unpublished data). Using these two antibodies, we have developed a sensitive and rapid solid-phase immunoradiometric assay (IRMA) for IFN-y. Our report shows that this assay can be used as a specific probe for biologically active human IFN-y.
MATERIAL AND METHODSPreparation of IFN-y and Sources of Other IFNs. Human IFN-y was produced in the cultures of lymphocyte-rich plateletpheresis residue induced with phytohemagglutinin and phorbol 12-myristate 13-acetate. It was partially purified by a four-step protocol (20) Preparation of Bi Antibody-Coated Polystyrene Beads. Polystyrene beads, 0.64 cm in diameter (Precision Plastic Balls, Chicago), were washed with ethanol and phosphatebuffered saline (Pi/NaCl, pH 7.0). Coating of the beads with B1 antibody was performed...